Imaging Prostate Cancer: A Multidisciplinary Perspective1

H Hricak, PL Choyke, SC Eberhardt, SA Leibel… - Radiology, 2007 - pubs.rsna.org
The major goal for prostate cancer imaging in the next decade is more accurate disease
characterization through the synthesis of anatomic, functional, and molecular imaging …

PET imaging in oncology

R Bar-Shalom, AY Valdivia, MD Blaufox - Seminars in nuclear medicine, 2000 - Elsevier
The role of positron emission tomography (PET) during the past decade has evolved rapidly
from a pure research tool to a methodology of enormous clinical potential. Perhaps the most …

Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography

N Tahara, H Kai, M Ishibashi, H Nakaura… - Journal of the American …, 2006 - jacc.org
Objectives: We investigated whether simvastatin attenuates plaque inflammation by using
18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) co-registered with …

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate …

SM Hillier, KP Maresca, FJ Femia, JC Marquis… - Cancer research, 2009 - AACR
Prostate-specific membrane antigen (PSMA) is expressed in normal human prostate
epithelium and is highly up-regulated in prostate cancer. We previously reported a series of …

CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings

H Choi, C Charnsangavej, SC Faria… - American Journal of …, 2004 - Am Roentgen Ray Soc
OBJECTIVE. We correlated changes in tumor density on CT with changes in glucose
metabolism, or the maximum standardized uptake value (SUVmax), on FDG PET and sought …

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer

SM Hillier, KP Maresca, G Lu, RD Merkin… - Journal of Nuclear …, 2013 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and
small-molecule radiopharmaceuticals targeting PSMA rapidly detect the location and extent …

Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine

A Becherer, G Karanikas, M Szabó, G Zettinig… - European journal of …, 2003 - Springer
Imaging of amino acid transport in brain tumours is more sensitive than fluorine-18 2-fluoro-
deoxyglucose positron emission tomography (PET). The most frequently used tracer in this …

Detection of unexpected additional primary malignancies with PET/CT

T Ishimori, PV Patel, RL Wahl - Journal of Nuclear Medicine, 2005 - Soc Nuclear Med
This study evaluated the yield of whole-body 18F-FDG PET/CT for the detection of
unexpected 18F-FDG-avid additional primary malignant tumors in patients being evaluated …

Radiologic measurements of tumor response to treatment: practical approaches and limitations

C Suzuki, H Jacobsson, T Hatschek, MR Torkzad… - Radiographics, 2008 - pubs.rsna.org
Objective response assessment is important to describe the treatment effect of anticancer
drugs. Standardization by using a “common language” is also important for comparison of …

Increased Uptake of the Apoptosis-imaging Agent 99mTc Recombinant Human Annexin V in Human Tumors after One Course of Chemotherapy as a Predictor of …

T Belhocine, N Steinmetz, R Hustinx, P Bartsch… - Clinical Cancer …, 2002 - AACR
Purpose: Many anticancer therapies exert their therapeutic effect by inducing apoptosis in
target tumors. We evaluated in a Phase I study the safety and the feasibility of 99mTc …